{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:11:57Z","timestamp":1719533517341},"reference-count":8,"publisher":"Georg Thieme Verlag KG","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:p>Die Lebenserwartung von Menschen mit Down-Syndrom ist in den letzten Jahrzehnten\n                    deutlich gestiegen und betr\u00e4gt aktuell etwa 60 Jahre 1. In Deutschland leben etwa 50.000 Menschen mit\n                    Trisomie 21. Da das Amyloid Precursor Protein Gen sich auf Chromosom 21 befindet,\n                    haben Menschen mit Down-Syndrom ein hohes Risiko, an einer Alzheimer-Demenz zu\n                    erkranken. In einer L\u00e4ngsschnittstudie waren 23% der\n                    (\u00fcberlebenden) Menschen mit Down-Syndrom mit 50 Jahren, 45% mit 55\n                    Jahren und 88% mit 65 Jahren an Demenz erkrankt 2. Menschen mit Down Syndrom machen einen gro\u00dfen Teil\n                    pr\u00e4seniler Alzheimer-Erkrankungen aus. Histologisch finden sich\n                    Amyloidablagerungen bei praktisch allen Menschen mit Down-Syndrom ab dem 30.\n                    Lebensjahr 3.<\/jats:p>","DOI":"10.1055\/a-1895-6817","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T22:46:37Z","timestamp":1663195597000},"page":"394-395","source":"Crossref","is-referenced-by-count":0,"title":["Down-Syndrom und Alzheimer-Demenz"],"prefix":"10.1055","volume":"90","author":[{"given":"Claus-W.","family":"Wallesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"e2212910","DOI":"10.1001\/jamanetworkopen.2022.12910","article-title":"Association of Alzheimer Disease with life expectancy in people with Down\n                    syndrome","volume":"5","author":"M F Iulita","year":"2022","journal-title":"Jama Netw Open"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/jir.12390","article-title":"A prospective 20-year longitudinal follow-up of dementia in persons with Down\n                    syndrome","volume":"61","author":"M McCarron","year":"2017","journal-title":"J. Intellect Disabil Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/nbdi.1996.0003","article-title":"Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down\n                    syndrome: implications for initial events in amyloid plaque formation","volume":"3","author":"C A Lemere","year":"1996","journal-title":"Neuobiol Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for\n                    Alzheimer disease biomarkers-","volume":"87","author":"C R Jack","year":"2016","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.3390\/molecules27103244","article-title":"Pharmacological approaches to the tretament of dementia in Down Syndrome: A\n                    systematic review of randomized clinical studies","volume":"27","author":"L Cavalcanti de Oliveira","year":"2022","journal-title":"Molecules"},{"issue":"433","key":"ref7","first-page":"444","article-title":"Kognition bei Down-Syndrom: Entwicklung \u00fcber die Lebensspanne und\n                    neuropsychologische Diagnostik im Erwachsenenalter","volume":"89","author":"S V Loosli","year":"2021","journal-title":"Fortschr Neurol Psychiatr"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/S0140-6736(20)30689-9","article-title":"Clinical and biomarker changes of Alzheimer`s disease in adults with\n                    Down syndrome: a cross sectional study","volume":"395","author":"J Fortea","year":"2020","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(21)00129-0","article-title":"Diagnostic and prognostic performance and longitudinal changes in plasma\n                    neurofilament light chain concentrations in adults with Down syndrome: a cohort\n                    study","volume":"20","author":"M Carmona-Iragui","year":"2021","journal-title":"Lancet Neurol"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1895-6817.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T18:44:27Z","timestamp":1719513867000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1895-6817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":8,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2022,9,14]]},"published-print":{"date-parts":[[2022,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1895-6817","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}